{"filing":{"accession_number":"0001437749-26-025167","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"mbrx20260729_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/mbrx20260729_8k.htm"},"events":[{"id":22848,"run_id":20681,"accession_number":"0001437749-26-025167","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Moleculin disclosed updated preliminary blinded interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin for R/R AML, reporting a 37% composite complete remission rate in 62 evaluable subjects, with notably consistent efficacy (37% CRc) in the 48% subgroup that had failed prior venetoclax therapy. This is a material clinical trial milestone disclosure that does not fit the earnings_release category (which typically reports financial results) but represents a significant operational/clinical development event that would affect investor assessment of the company's lead program advancement and regulatory pathway.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22921,"accession_number":"0001437749-26-025167","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Moleculin disclosed updated preliminary blinded interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin for R/R AML, reporting a 37% composite complete remission rate in 62 evaluable subjects, with notably consistent efficacy (37% CRc) in the 48% subgroup that had failed prior venetoclax therapy. This is a material clinical trial milestone disclosure that does not fit the earnings_release category (which typically reports financial results) but represents a significant operational/clinical development event that would affect investor assessment of the company's lead program advancement and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:33:50.719014+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22921,"accession_number":"0001437749-26-025167","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Moleculin disclosed updated preliminary blinded interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin for R/R AML, reporting a 37% composite complete remission rate in 62 evaluable subjects, with notably consistent efficacy (37% CRc) in the 48% subgroup that had failed prior venetoclax therapy. This is a material clinical trial milestone disclosure that does not fit the earnings_release category (which typically reports financial results) but represents a significant operational/clinical development event that would affect investor assessment of the company's lead program advancement and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:33:50.719014+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-07-31"}]}